Cancer Susceptibility Candidate 9 (CASC9): A Novel Targetable Long Noncoding RNA in Cancer Treatment

• Published in: Translational oncology Vol. 13; no. 8; p. 100774
• Main Authors: Sharma, Uttam, Barwal, Tushar Singh, Acharya, Varnali, Tamang, Suraksha, Vasquez, Karen M., Jain, Aklank
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2020; Neoplasia Press; Elsevier
• Subjects: Review article
• ISSN: 1936-5233; 1936-5233
• DOI: 10.1016/j.tranon.2020.100774

Based on epidemiological data provided by the World Health Organization (2018), cancer is the second most prevalent cause of death worldwide. Several factors are thought to contribute to the high mortality rate in cancer patients, including less-than-optimal diagnostic and therapeutic strategies. Thus, there is an urgent need to identify accurate biomarkers with diagnostic, prognostic, and potential therapeutic applications. In this regard, long noncoding RNAs (lncRNAs) hold immense potential due to their regulatory roles in cancer development and associated cancer hallmarks. Recently, CASC9 transcripts have attracted significant attention due to their altered expression during the pathogenesis of cancer and their apparent contributions to various cancer-associated phenotypes involving a broad spectrum of molecular mechanisms. Here, we have provided an in-depth review describing the known functions of the lncRNA CASC9 in cancer development and progression.